^
Association details:
| Biomarker: | RNPEP overexpression |
|---|---|
| Cancer: | Multiple Myeloma |
| Drug: | Melflufen (melphalan flufenamide) (Alkylating agent) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Novel Peptide-drug Conjugate Melflufen Efficiently Eradicates Bortezomib-resistant Multiple Myeloma Cells Including Tumor-initiating Myeloma Progenitor Cells
Published date:
06/12/2021
Excerpt:
...melflufen represents a novel treatment option that is able to eradicate drug-resistant myeloma clones characterized by elevated aminopeptidase B expression.
DOI:
10.1097/HS9.0000000000000602
Source:
Title:
Aminopeptidase Expression in Multiple Myeloma Associates with Disease Progression and Sensitivity to Melflufen
Published date:
03/26/2021
Excerpt:
We analyzed the expression of 39 aminopeptidase genes in MM samples from 122 patients treated at Finnish cancer centers and 892 patients...Sensitivity to melflufen was detected ex vivo in 11/15 MM patient samples, and high sensitivity was observed, especially in relapsed/refractory samples. Survival analysis revealed that high expression of XPNPEP1, RNPEP, DPP3, and BLMH (p < 0.05) was associated with shorter overall survival.
DOI:
10.3390/cancers13071527
